Its difficult to distinguish direct anti-inflammatory effects from the benefits of weight loss and improved metabolic health, but the pattern is consistent enough to warrant further study. A 2025 study found that RA patients with a BMI over 27 taking GLP-1 medications showed improvements in symptoms and disease activity
Preclinical studies demonstrated that AOD-9604 was generally safe after chronic oral application in rats and cynomolgus monkeys, with no genotoxic concerns identified
Even so, consumers are put in an awkward place
Its ability to enhance healing processes without the need for additional carriers simplifies treatment protocols and makes it a more convenient option for patients and healthcare providers alike
Weight regain varies by individual, but many people begin regaining weight within the first few months after stopping semaglutide, with the early months representing the highest-risk period
The remainder of this analysis will review the law and risks related to this decision